Advanced Cell Technology, a US pharmaceutical company, has been granted benefi cial “orphan drug” status under the Orphan Drug Act by the US Food and Drug Administration for an embryonic stem cell therapy which it is developing to treat Stargardt’s Macular Dystrophy, a rare form of blindness. The Act helps to speed therapies for diseases affl icting fewer than 200,000 Americans, which otherwise makes developing drugs for them unattractive to pharmaceutical companies. Its benefi ts include tax breaks, access to grant funding for clinical trials, accelerated FDA approval and up to seven years of market exclusivity.
Register Now As you are not an existing subscriber please register for your free daily legal newsfeed service.Register
If you have any questions about the service please contact email@example.com or call Lexology Customer Services on +44 20 7234 0606.
US company granted “orphan drug status” to find cure for rare blindness syndrome
If you are interested in submitting an article to Lexology, please contact Andrew Teague at firstname.lastname@example.org.
Senior Patent Counsel
Royal DSM NV